Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 11/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.56 |
| ▸ | DCLK1 | O15075 | 7/20 | 0.56 |
| ▸ | BRD4 | O60885 | 4/20 | 0.56 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.56 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.50 |
| ▸ | TAF1 | P21675 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850465 | 0.91 | MAPK7 (0.55) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL29986158 | 0.85 | LRRK2 (0.63) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL29850704 | 0.83 | LRRK2 (0.61) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL23144757 | 0.83 | LRRK2 (0.58) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL23144758 | 0.80 | LRRK2 (0.61) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL17465855 | 0.78 | NUAK1 (0.67) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL20628385 | 0.74 | DCLK1 (0.75) | MAPK7LRRK2DCLK1PIK3CDAURKA | |
| SCHEMBL16065781 | 0.74 | LRRK2 (0.70) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL20628384 | 0.73 | PIK3CD (0.67) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL17465830 | 0.73 | LRRK2 (0.85) | MAPK7LRRK2DCLK1BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034132-B1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA FARBER CANCER INST INC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| EP-4034132-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | OXSR1, MAPK1, NGFR | MAPK7 30/4885LRRK2 340/4885DCLK1 2710/4885 |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | MAPKAPK5, DUSP5, MAP3K5 | MAPK7 60/4885LRRK2 427/4885DCLK1 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.